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Abstract
Large segmental defects in bone fail to heal and remain 
a clinical problem. Muscle is highly osteogenic, and 
preliminary data suggest that autologous muscle tissue 
expressing bone morphogenetic protein-2 (BMP-2) 
efficiently heals critical size defects in rats. Translation 
into possible human clinical trials requires, inter alia, 
demonstration of efficacy in a large animal, such as the 
sheep. Scale-up is fraught with numerous biological, 
anatomical, mechanical and structural variables, which 
cannot be addressed systematically because of cost and 
other practical issues. For this reason, we developed a 
translational model enabling us to isolate the biological 
question of whether sheep muscle, transduced with 
adenovirus expressing BMP-2, could heal critical size 
defects in vivo. Initial experiments in athymic rats noted 
strong healing in only about one-third of animals because 
of unexpected immune responses to sheep antigens. For 
this reason, subsequent experiments were performed with 
Fischer rats under transient immunosuppression. Such 
experiments confirmed remarkably rapid and reliable 
healing of the defects in all rats, with bridging by 2 weeks 
and remodelling as early as 3-4 weeks, despite BMP-2 
production only in nanogram quantities and persisting for 
only 1-3 weeks. By 8 weeks the healed defects contained 
well-organised new bone with advanced neo-cortication 
and abundant marrow. Bone mineral content and 
mechanical strength were close to normal values. These 
data demonstrate the utility of this model when adapting 
this technology for bone healing in sheep, as a prelude to 
human clinical trials.
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Although gene therapy is usually associated with the 
treatment of rare Mendelian diseases, it holds much 
potential for solving more common clinical problems, 
such as those presented by injuries to the musculoskeletal 
system (Evans and Robbins, 1999; Evans et al., 2004). 
Bone healing is a case in point (Pensak and Lieberman, 
2013; Baltzer et al., 2000; Niyibizi et al., 1998). Even 
though the long bones constitute one of the few organs 
in the body that can regenerate spontaneously without 
scarring, large segmental defects beyond a certain critical 
size fail to heal (Muschler et al., 2010).
 Depending upon the setting, distraction osteogenesis 
and osseous autografting are the treatments of choice 
for the clinical management of large segmental defects 
(reviewed by DeCoster et al., 2004). While often 
successful, the former technique is inconvenient, slow 
and often painful. Autografting, on the other hand, is 
constrained by the limited amount of autologous bone 
available for grafting and donor site morbidity. Bone 
harvested from cadavers provides an alternative source 
of graft material and is available in almost unlimited 
quantities. However, the processing of allograft bone kills 
its cells, so that the implanted material is dead bone that 
fails to integrate with the adjacent living bone or remodel. 
Structural allografts thus accumulate microfractures and 
ultimately fail (DeCoster et al., 2004).
 Much research focuses on improving the treatment of 
large segmental defects through regenerative approaches 
using various combinations of novel scaffolds, osteogenic 
growth factors, progenitor cells and mechanical stimulation 
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(Evans, 2013; Dumic-Cule et al., 2015). Our group has 
adopted the strategy of developing simple, intra-operative 
technologies that do not require scaffolds or the ex vivo 
expansion of autologous cells (Evans et al., 2007).
 From this perspective, the highly osteogenic properties 
of skeletal muscle are conspicuous and best exemplified 
by the disease fibrodysplasia ossificans progressiva 
(FOP). An activating mutation in Alk2, that encodes 
a bone morphogenetic protein (BMP) receptor, leads 
to progressive heterotopic ossification through an 
endochondral process (Shore et al., 2006). This confirms 
that a sustained BMP signal promotes osteogenesis in 
human skeletal muscle, which is important given the often-
poor correlation between results obtained in rodent models 
and clinical data from human subjects (Seok et al., 2013). 
The occurrence of heterotopic ossification in muscle after 
blast injuries, burns, traumatic brain injury, spinal cord 
injury and certain types of joint surgery further illustrates 
its osteogenic potential (Nauth et al., 2012 ).
 Gene transfer offers one way to provide a sustained 
BMP signal in vivo. Of the various gene transfer 
vectors, adenovirus offers many advantages because it is 
straightforward to produce at high titer, is highly infectious 
and has been widely used in human clinical trials (Crystal, 
2014). Moreover, the natural history of the recombinant 
virus ensures its biological clearance, and hence loss of 
transgene expression, within about 6 weeks (Baltzer et al., 
1999). This time-line seems well matched to the needs of 
bone healing.
 From such considerations we designed a strategy to 
heal bone based upon the genetic modification of muscle 
using recombinant adenovirus vectors carrying human 
BMP-2 cDNA (Ad.BMP-2). Ultimately, this could be 
implemented intra-operatively, with muscle biopsies 
harvested, genetically modified and implanted into a 
defect in one session. The physical properties of muscle 
are such that no scaffold is needed. This strategy was tested 
previously in rats, with encouraging preliminary data that 
also demonstrated the promise of autologous fat in this 
regard (Evans et al., 2009).
 Translating research findings into clinical protocols 
requires demonstration of efficacy in large animal models, 
and this step has become a bottleneck for the field of 
bone healing (Evans, 2010; Evans, 2011a,b). Sheep are 
a favoured species in translational studies of this kind, 
because of their size, weight and bone structure (Muschler 
et al., 2010). Previous attempts to heal osseous lesions 
in sheep by gene therapy have met with mixed success 
(Egermann et al., 2006a,b). Reports that sheep and human 
osteoprogenitors are less responsive to BMP-2 than 
equivalent rodent cells (Diefenderfer et al., 2003) may be 
of relevance.
 Because sheep and other large animals are expensive 
to buy and cumbersome to house, operate and process, it 
is not possible to perform multiple, large, well-powered 
studies to examine each variable in the same way as is usual 
with rodents. For this reason, we developed a translational 
model whereby genetically modified sheep muscle or 
fat were implanted into diaphyseal, femoral defects in 
immunosuppressed rats. This enabled us to isolate and 
study the crucial biological question of whether genetically 
modified sheep tissues could heal a critical size defect in 
vivo, while keeping all other variables constant. The results 
were dramatic.
Materials and Methods
Preparation of adenovirus vectors
First generation adenovirus (ΔE1, ΔE3), serotype 5, 
carrying human BMP-2 cDNA (Ad.BMP-2) or green 
fluorescent protein (GFP) cDNA (Ad.GFP) under the 
transcriptional control of the human cytomegalovirus early 
promoter were constructed by cre-lox recombination as 
previously described (Gouze et al., 2004; Mi et al., 2003). 
Viruses were propagated in 293 cells (ATCC, Manassas, 
VA, USA), purified on caesium-chloride gradients, and 
dialysed against 10 mM Tris-HCl (pH 7.8), 150 mM NaCl, 
10 mM MgCl2, and 4 % sucrose buffer. Viral titers were 
estimated as 1012 to 1013 viral particles (vp)/mL by optical 
density and 1010 to 1011 plaque forming units (pfu)/mL by 
standard plaque assay.
Genetic modification of muscle and fat implants
Sheep muscle and fat were freshly harvested from healthy 
sheep being euthanised for other purposes at the BIDMC 
Slosberg Landay Animal Facility, the Department of 
Orthopaedic Surgery at Massachusetts General Hospital 
(Boston, MA, USA), and The Cummings School of 
Veterinary Medicine (North Grafton, MA, USA).
 Soleus muscle and sub-cutaneous fat were harvested 
aseptically from American Polypay female sheep, 
approximately 18 months of age, and carefully prepared to 
form slices approximately 2 mm thick; 4 mm × 2 mm discs 
were produced with a 4 mm skin biopsy punch. Groups 
of 4 discs were placed into wells of 48-well plates and a 
50 μL aliquot of adenovirus suspension (1010 vp/well) was 
added to each well. The plates were incubated (37 °C; 5 % 
CO2) for 2 h. The discs were then washed with phosphate 
buffered saline (PBS), and subsequently 1 mL of medium 
(Dulbecco’s Modified Essential Medium, 10 % foetal 
calf serum, 50 µg/mL ascorbic acid, 10 mM β-glycerol 
phosphate) was added to each well. Conditioned medium 
was collected at 72 h and BMP-2 content measured using a 
commercial ELISA kit (R&D Systems, Minneapolis, MN, 
USA).
Rats
Male Fischer F344 rats were purchased from Charles River 
Laboratory (Wilmington, MA, USA). Athymic rats were 
purchased from Charles River Laboratory and Taconic 
Farms (Germantown, NY, USA). All animals were 12 
weeks of age at the time of surgery. Rats were housed in 
a central animal care facility with 12-h light cycles and 
were given chow and water ad libitum. Animal care and 
experimental protocols were followed in accordance with 
National Institutes of Health guidelines and approved by 
the Beth Israel Deaconess Medical Center Institutional 
Animal Care and Use Committee. The numbers and types 
of rats assigned to the various experiments are shown in 
Table 1.
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Surgical procedure
Animals were divided randomly into the experimental 
groups described below. A 5 mm, critical-sized, mid-
femoral defect was created in the right hind limb of each 
rat and used in all the experiments. Briefly, Fischer rats 
were anaesthetised by administration of isoflurane (2 % 
at 2 L/min) and given antibiotic (cefazolin, 20 mg/kg) 
and analgesic (meloxicam, 1.0 mg/kg) subcutaneously 
before surgery.
 Under sterile conditions, a 4 cm incision was made on 
the posterolateral thigh. The lateral intermuscular septum 
with respect to the femur was dissected to expose the 
diaphysis of the femur. The periosteum was removed on 
the anterolateral femur. Using a demo fixator as a guide, 
four predrilled pin holes were made in the central portion 
of the femoral shaft with a sterile 0.79 mm drill bit. The 
external fixator (RISystem AG, Davos, Switzerland) was 
then secured in position by screwing 4 precise pins into 
both cortices of the rat femora through these predrilled 
holes and the external fixator. A saw guide was used to 
position and create the 5 mm segmental defect using a 
0.22 mm wire Gigli saw. After the defect was created, the 
saw guide was removed and 4 discs of sheep muscle or fat 
were press-fit into the defect area created in the rat femur. 
The wound was repositioned in layers with 3-0 Vicryl 
sutures and the incision site closed using Autoclip wound 
clips.
Immunosuppression
FK506 was dissolved in ethanol:Tween 80:saline – 
1:0.2:8.8 (v/v) to a concentration of 6.67 mg/mL FK506. 
SEW2871 was dissolved in ethanol:Tween 80:saline 
– 2.7:0.2:7.1 (v/v) to a concentration of 3.33 mg/mL 
SEW2871. These two solutions were mixed in a 1:1 ratio 
to provide a solution containing 3.33 mg/mL FK506 and 
1.66 mg/mL SEW2871. Each rat received a daily100 µL 
subcutaneous injection of this mixture during the period 
of immunosuppression.
Immunoassays
Cell-mediated immune response to sheep cells
Sheep fat cells were irradiated at 30 Gy and plated out in 
triplicate in 96-well U bottomed plates (Greiner Bio-One, 
Stonehouse, UK), serially diluted 1:2 from 1 × 104 cells/
well down to 1.25 × 103 cells/well. Splenocytes were 
harvested from the spleens of naïve and transplanted rats 
and depleted of red-blood cells using Red Blood Cell 
Lysing Buffer (0.155 M ammonium chloride in 0.01 
M Tris-HCl buffer, Sigma, St Louis, MO, USA), and 
B-cells using CD45RA microbeads (Miltenyi Biotech, 
Cambridge, MA, USA) according to the manufacturer’s 
instructions. The splenocytes were then added to the 
plate at 105 cells/well (final volume: 200 μL/well). After 
5 d at 37 °C, splenocyte proliferation was assessed by 
bromodeoxyuridine (BrdU) incorporation over 6 h using 
a colorimetric immunoassay kit (Roche Applied Science, 
Pleasanton, CA, USA) according to the manufacturer’s 
instructions.
Humoral response to sheep cells
Serum samples from naive and transplanted rats were 
collected and analysed for the presence of anti-sheep IgG 
and IgM by FACS using sheep fat cells as targets. Sheep 
cells were removed from culture and resuspended at 2 × 106 
cells/mL in PBS; 1 × 105 cells were incubated in triplicate 
for 30 min at 4 °C with serum samples (harvested at the 
indicated time-points and previously heat inactivated at 
56 °C for 30 min) at a final dilution of 1 in 10. Cells were 
washed twice, and then incubated with either a 1 in 100 
dilution of goat anti-rat IgG FITC or a 1 in 100 dilution 
of goat anti-rat IgM FITC (both from AbD Serotec, 
Raleigh, NC, USA) for a further 30 min at 4 °C. The 
cells were then fixed with 4 % paraformaldehyde in PBS, 
washed twice, and analysed by flow cytometry. Data are 
expressed as a fluorescence index created by dividing the 
mean fluorescence intensity (MFI) of each experimental 
serum sample by the MFI of pooled serum derived from 
multiple naïve rats.
Measurement of BMP-2 in extracts of the defect area
To assess the temporal expression of BMP-2 in the femoral 
defect after implantation of Ad.BMP-2 transduced tissue 
grafts, the tissue in the defect area was collected at 3, 7, 
21, 35 and 56 d and pulverised in stainless steel grinding 
jars using a TissueLyser II (Qiagen, Hilden, Germany). The 
resulting tissue powder was extracted with T-PER tissue 
protein extraction solution (Thermo Fisher Scientific, 
Rockford, IL, USA) containing protease inhibitors to 
release protein. The supernatant was collected and diluted 
10-fold before BMP-2 measurement using a commercial 
ELISA kit (R&D Systems).





Athymic Sheep Fat _ Ad.BMP-2 6
Sheep Muscle _ Ad.BMP-2 12
Fischer 344
Sheep Fat + Ad.BMP-2 3
Sheep Muscle + Ad.BMP-2 55
Sheep Muscle _ Ad.BMP-2 17
Sheep Muscle + Ad.GFP 6
rhBMP-2 11 µg + Collagen sponge _ N/A 6
rhBMP-2 11 µg + Collagen sponge + N/A 6
Table 1. Groups of animals used in the experiments described in this paper.
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Radiographic evaluation
Serial, weekly radiography using a digital dental X-ray 
unit was performed on rats under general anaesthesia. Rats 
were ventrally positioned and the X-ray sensor was placed 
under the defect area of each femur.
Micro-computed tomography (µCT)
The architecture of newly formed bone in the rat segmental 
defects was examined with a desktop micro-tomographic 
imaging system (µCT40, Scanco Medical AG, Bassersdorf, 
Switzerland) equipped with a 10 mm focal spot microfocus 
X-ray tube. Femoral defects were scanned using a 20 µm 
isotropic voxel size, at 55 keV energy, 200 ms integration 
time, with approximately 500 µCT slices per specimen. 
Evaluation of only a 4 mm (~220 slices) central region 
of the defects was used to exclude any pre-existing intact 
cortical bone. Total cross-sectional area or the callus size 
of the defect (TA, mm2), bone area (BA, mm2), and cortical 
thickness were calculated from µCT images. Images were 
thresholded using an adaptive-iterative algorithm and 
morphometric variables were computed from the binarised 
images using direct, 3D techniques that do not rely on any 
prior assumptions about the underlying structure.
Dual-energy X-ray absorptiometry (DXA)
DXA measurements (Bone mineral content, BMC 
(grammes)) of the defect area were obtained with PIXImus2 
apparatus (GE-Lunar, Madison, WI, USA). Briefly, each 
femoral defect was placed on a lucite block during scanning 
to simulate soft tissue. The scans were acquired using 
small animal high-resolution mode. All specimens were 
evaluated at 8 weeks in the area corresponding to the region 
of the critical-sized bony defect.
Ex vivo torsion testing
Specimens were tested to failure in torsion to evaluate 
mechanical properties of the healed defect in shear. Before 
the test, both ends of each specimen were embedded 
in polymethylmethacrylate to provide a reproducible 
gripping interface with the testing fixture. All femora 
were tested to failure under regular deformation control 
and at the constant deformation rate of 5 rad/min. Angular 
Fig. 1. Bone healing in athymic rats. Radiologic findings: Representative images of X-ray (A, C) and corresponding 
high resolution µCT (B, D) taken at 8 weeks, showing the typical range of bone healing efficacy in athymic rats 
receiving grafts of genetically modified sheep fat (A, B) or muscle (C, D). Arrows in the X-ray images of rats # 2 and 
5 show the edges of the defect. Immunologic findings: Rat anti-sheep IgG xenoantibody responses in six different 
rats at 8 weeks following sheep muscle implantation (E). Samples were run in triplicate.
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deformation and applied load data were acquired at 10 Hz. 
The torque and rotation data were used to calculate the 
torsional stiffness and strength of the healed defect.
Histology
The defect regions were removed from euthanised rats and 
fixed in 4 % ice cold paraformaldehyde for 48 h at 4 °C 
before decalcification with 20 % EDTA in 0.1 M phosphate 
buffer (pH 7.4). Extracted femora were maintained in 
EDTA solution for 4 weeks and tested with a needle 
as the decalcification proceeded. The specimens were 
subsequently dehydrated in graded ethanol and embedded 
in paraffin. Serial 5 µm paraffin sections were placed on 
poly-L-lysine-coated slides, and dried overnight. Sections 
were stained with either haematoxylin-eosin or safranin 
orange-fast green, and then examined and photographed 
under light microscopy.
Statistical analysis
Comparisons of continuous variables between two 
treatment groups were performed using a two-tailed 
Student’s t-test, and between three groups by analysis of 
variance (One Way-ANOVA). If the difference between 
the control and the treatment groups was significant, a 
post-hoc test (Tukey) was performed. Data are presented 
as means ± standard deviation (SD), unless otherwise noted 
as means ± standard error of a mean (SEM). The results 
were taken to be statistically significant at a probability 
level of p < 0.05.
Results
Bone healing in athymic rats
Athymic rats were used because of their reported ability 
to accept xenografted tissue. Their use in an orthopaedic 
context has been published previously (Burastero et al., 
2010; Schmitt et al., 2013; Yuan et al., 2013).
 Three days after transduction with Ad.BMP-2, discs 
of sheep muscle each secreted 1.2 ± 0.2 ng BMP-2/disc/d. 
Discs of sheep fat produced 3.3 ± 0.3 ng BMP-2/disc/d. At 
this stage, both tissues were implanted into athymic rats. In 
preliminary screening experiments, 4 genetically modified 
muscle discs were implanted into 5 mm segmental defects 
Fig. 2. Bone healing in immunosuppressed Fischer 344 rats. Radiologic findings: Representative X-rays (A, C) and 
corresponding high resolution µCT (B, D) scans taken at 8 weeks, showing new bone formation in rats receiving grafts 
of genetically modified sheep fat (A, B) or muscle (C, D). Immunologic findings: (E) Proliferation of splenocytes 
recovered from rats receiving grafts of genetically modified sheep muscle. Data are presented as mean values × 103 
± SEM; * and $ denote a significant difference (p < 0.05) relative to naïve control group and immunocompetent 
group (Immune+) group, respectively. (F) Rat anti-sheep IgM responses at 8 d. (G) IgG xenoantibody responses over 
time following sheep muscle implantation.  indicates a significant difference when compared to control (Immune+) 
group at respective time-points (p < 0.05). For the immunosuppressed (Immune-) group, no significant difference 
existed between different time-points. All immunoassays were run in triplicate.
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in each of 6 athymic rats, and 4 genetically modified fat 
discs were implanted into each of 3 athymic rats. Healing 
was monitored by X-ray and micro-computed tomography 
(µCT). None of the defects receiving genetically modified 
fat healed. A substantial amount of bone formed in only 
one of the three defects treated in this way (Fig. 1A, B rat 
#1), while the other two defects showed no healing (e.g. 
Fig. 1A, B rat #2). With genetically modified muscle discs, 
one rat did not heal (Fig. 1C, D rat #3); defects of 3 rats 
partially healed (e.g. Fig. 1C, D rat #4); two rats healed 
rapidly, and by 8 weeks showed complete bridging by 
X-ray (e.g. Fig. 1C, rat #5) and µCT (e.g. Fig. 1D, rat #5).
 Further analysis revealed that the variation in healing 
when using genetically modified muscle was associated 
with the level of anti-sheep IgG present in the serum 
(Fig.1E). In particular, high levels of anti-sheep IgG 
production were associated with impaired healing (e.g. rat 
#3; Fig. 1C, D and E), while low or absent ant-sheep IgG 
production was associated with complete bridging (e.g. 
rat#5; Fig. 1C, D and E).
 Thus, certain athymic rats mounted immune responses 
to the xenografted sheep tissue, leading to the hypothesis 
that immune mechanisms were limiting healing. Because 
similar data were obtained with athymic rats obtained from 
2 different suppliers (data not shown), we decided instead 
to use wild-type Fischer 344 rats and determine whether 
immunosuppression would enable the engraftment of sheep 
tissues and allow bone healing to occur.
Bone healing in immunosuppressed Fischer rats
In a preliminary study, 9 rats were immunosuppressed 
continuously with a combination of FK506 (tacrolimus) 
Fig. 3. Serial radiographs and µCT scans of femoral defects treated with genetically modified sheep muscle. Critical-
sized segmental femoral defects in Fischer F344 rats were implanted with Ad-BMP2 transduced sheep muscle grafts 
and transiently immunosuppressed. X-rays (A) were taken weekly and the defects were then harvested for µCT 
scans (B, 3-dimensional and coronal images; C, cross sectional images) at progressive time-points after surgery. 
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and SEW2871. Three of these rats received genetically 
modified sheep fat, and 6 received genetically modified 
sheep muscle.
 Immunosuppression improved the formation of bone 
within defects receiving genetically modified fat, but 
only one of the 3 defects bridged with new bone (Fig. 
2A, B). However, femoral defects of all six rats receiving 
genetically modified muscle had bridged 8 weeks after 
receiving the implant; three examples are shown in Fig. 
2C, D. This was associated with suppressed cell-mediated 
immune responses when splenocytes from these rats 
were co-cultured with irradiated sheep cells (Fig. 2E). 
Immunosuppression also reduced the secretion of anti-
sheep IgM into the serum (Fig. 2F) by 8 d, and prevented 
the progressive production of anti-sheep IgG over the 
course of the experiment (Fig. 2G). Both of these responses 
were strongly inhibited by the immunosuppressive 
regimen.
 In  subsequent  exper iments  the  per iod  of 
immunosuppression was reduced to 3 weeks. This was 
found sufficient to eliminate anti-sheep immune responses 
for the entire 8 weeks of the experiment (data not shown) 
and allow healing of the defects.
Time course of healing in transiently 
immunosuppressed Fischer rats
Based upon the data shown in Fig. 2, a larger study 
comprising 24 transiently immunosuppressed and 
12 unsuppressed control rats, was undertaken using 
genetically modified sheep muscle. An additional series 
of 6 transiently immunosuppressed rats received implants 
of sheep muscle transduced with adenovirus carrying GFP 
cDNA (Ad.GFP) (Table 1). All 24 immunosuppressed rats 
successfully healed their femoral defects in the presence 
of genetically modified sheep muscle expressing BMP-2; 
data pertaining to these animals are given below. In none of 
the unsuppressed rats or rats receiving GFP+ muscle were 
the defects healed (data not shown). Healing of defects 
in immunosuppressed rats receiving genetically modified 
sheep muscle was studied in greater detail.
 A time-course experiment provided X-ray and µCT 
evidence that, in 6 out of the 24 animals, mineral began to 
be deposited in the defect one week after implantation of 
the genetically modified sheep muscle (Fig. 3). Complete 
bridging occurred in all animals by 2 weeks. Thereafter, 
vigorous re-modelling reduced the presence of trabecular 
bone and led to neo-cortication (Fig. 3).
 In an additional series of experiments, protein was 
extracted from the region of the defect and the BMP-2 
content measured by ELISA. As shown in Fig. 4, BMP-2 
content was high 3 d after implantation of the genetically 
modified muscle. This fell considerably by 1 week, and 
was undetectable at 3 weeks and beyond.
 Histological examination (Fig. 5) confirmed the 
radiologic data. At 1 week, staining with haematoxylin 
and eosin (H&E) showed the presence of the implanted 
muscle surrounded by an inflammatory cell infiltrate (Fig. 
5A, B). At 2 weeks, however, most of the muscle had 
been replaced by woven bone, with islands of residual 
cartilage still visible at 3 weeks as confirmed by staining 
with safranin orange-fast green (Fig. 5C). Lamellar bone 
began to appear at this point, with neo-cortication and the 
presence of marrow becoming increasingly prominent. 
By the time the experiment was terminated at 8 weeks, 
cortices had been formed, cartilage was no longer visible 
and an abundant marrow was present, with only a little 
intramedullary trabecular bone.
 At 8 weeks, the quality of the healed defects was 
assessed by dual-energy X-ray absorptiometry (DXA), 
quantitative µCT analysis and mechanical testing, 
using the equivalent position on the contralateral femur 
for comparison, and defects where rats had not been 
immunosuppressed as negative controls (Fig. 6). At this 
time the bone mineral content of the healed defects and the 
area of bone within the former defect were at near normal 
values (Fig. 6A, B). The total area within the defect was 
higher than normal (Fig. 6C), whereas the neo-cortices 
were thinner than normal (Fig. 6D). Mechanical testing 
showed that the healed bone was about 15 % stiffer than 
normal (Fig. 6E), and had recovered approximately 75 % 
of normal strength (Fig. 6F).
Possible influence of immunosuppressive drugs
To gain insight into the possible influence on the 
healing process of the immunosuppressive drugs, we 
undertook 2 series of experiments. In the first, we 
compared the properties of the bone formed by transiently 
immunosuppressed Fischer 344 rats with those of the bone 
Fig. 4. BMP-2 content of defects treated with 
genetically modified sheep muscle. BMP-2 content 
within extracts of rat femur defects was measured by 
ELISA and standardised to total protein. * indicates a 
significant increase (p < 0.05) of 3 d group compared 
to all other groups; $ indicates a significant increase 
(p < 0.05) of 1 week (wk) group compared to all 
later time points.
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Fig. 5. Histological appearance of defects during healing in transiently immunosuppressed rats. Ad.BMP-2 transduced 
sheep muscle grafts were implanted into defects in Fischer 344 rats and harvested for histology at different time-points. 
Rats were immunosuppressed for 3 weeks. (A) Representative images of sections stained with haematoxylin and eosin 
under low magnification (scale bar in 8 week panel = 1 mm). The boxed regions shown in panel A are shown at high 
magnification (scale bar = 0.2 mm) (B) and stained with safranin orange-fast green (scale bar = 0.2 mm) (C). Arrows 
in panel A, 1 week, indicate the pin holes of the external fixator. N indicates new cortical bone, C indicates cartilage, T 
indicates trabecular bone, M indicates bone marrow, SM indicates sheep muscle tissue, and F indicates fibrous tissue.
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formed by the sub-set of athymic rats that deposited bone 
after sheep muscle implantation in the absence of drugs. 
In the second, we assessed the influence of transient 
immunosuppression on the healing of defects in Fischer 
344 rats in response to recombinant, human (rh) BMP-2; 
these animals did not receive genetically modified muscle.
 Data from the first series of experiments (Fig. 7) 
confirm that, in the reliable absence of a xenograft response, 
genetically modified sheep muscle efficiently heals critical 
size defects in the rat femur, regardless of the presence or 
absence of immunosuppressive drugs. However, there are 
interesting differences in the appearance of the regenerates. 
Under µCT analysis, the bone formed in the athymic 
animals (Fig. 7B) appeared less mature, with far more 
intramedullary trabecular bone, than that formed under 
immunosuppression (Fig. 7C). The presence of residual 
cartilage in the athymic animals at 8 weeks (Fig. 7E), unlike 
the immunosuppressed animals (Fig. 7F), also suggests 
slower ossification and maturation.
 The mechanical properties, bone density and structure 
of the contralateral femora were not influenced by 
the immunosuppressive regimen (data not shown). 
Immunosuppression did not have a major effect on the 
healing of defects in response to rhBMP-2 (Fig. 8), further 
suggesting that the successful healing of osseous defects 
in rats by genetically modified sheep muscle could not be 
explained trivially by the effects of immunosuppression. 
All defects treated with rhBMP-2 healed.
Discussion
We have drawn attention to the highly osteogenic 
properties of muscle and suggested using these as the 
basis for improving the healing of large osseous defects. 
Based upon the genetics of the human disease FOP, a 
sustained BMP signal seems conducive to heterotopic 
ossification in muscle; in wild-type muscle, transduction 
with recombinant Ad.BMP-2 provides such a signal.
 The present data demonstrate that sheep skeletal 
muscle, transduced with Ad.BMP-2, can heal critical size 
defects in vivo very effectively. This suggests that there is 
no intrinsic reason involving the biology of muscle why 
there should be a species barrier that forbids the successful 
Fig. 6. Physical properties 
of the defects 8 weeks after 
implantation of genetically 
modified, sheep muscle 
grafts. (A) Bone mineral 
content, (B) Bone area, 
(C) Total callus area, (D) 
Cortical thickness, (E) 
Stiffness, (F) Strength 
measured as maximum 
torque. * denotes significant 
difference (p  <  0.05) 
when compared to intact 
contralateral femur group; 
 indicates significant 
difference (p < 0.05) relative 
t o  immunocompe ten t 
(Immune+) group. It was 
not possible to perform 
mechanical testing on 
non-immunosuppressed 
(Immune-) samples and 
these had no cortices.
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Fig. 7. Comparison of new bone formed in athymic rats and immunosuppressed Fischer 344 rats. Representative 
µCT images of normal diaphyseal femur (A), and repair bone formed 8 weeks after implantation of genetically 
modified sheep muscle in athymic rats (B) or in transiently immunosuppressed Fischer 344 rats (C). Representative 
histological images, shown at progressively higher magnification from left to right, display normal diaphyseal 
femur (D) and repair bone formed in athymic (E) and immunosupressed (F) rats. Sections were stained with 
H&E and safranin orange-fast green. Arrows in panels E and F, left hand panels, indicate the pin holes of external 
fixator. N indicates new cortical bone within the defects, M indicates bone marrow, T indicates trabecular bone, 
and F indicates fibrous tissue.
2D Sagittal
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translation of this technology to sheep, as a prelude to 
human trials. It is remarkable that such rapid and efficient 
healing was observed when the genetically modified 
sheep muscle discs were collectively making a total of 
only ~5 ng BMP-2/d at the time of implantation. By one 
week, the amount of BMP-2 in the defect had dropped 
by ~80 % and BMP-2 became undetectable by 3 weeks. 
This means that the total dose of BMP-2 delivered to the 
defect is probably in the nanogram range. If delivered as a 
recombinant protein, this amount of BMP-2 has no effect 
in this model; in our hands, 11 µg rhBMP-2 is normally 
needed to obtain robust, reliable healing (Betz et al., 2006; 
Betz et al., 2007; Glatt et al., 2009; Glatt et al., 2012).
 The time-course of healing is also noteworthy. 
Considerable amounts of bone had formed by 2 weeks, by 
which time the amount of BMP-2 within the defect had 
fallen by over 80 %. At 3 weeks, BMP-2 was no longer 
measurable. When the immunosuppressive drugs were 
withdrawn at this time, anti-sheep immune reactions did not 
develop and it was no longer necessary to immunosuppress 
to achieve reliable bone healing. Sheep muscle could no 
longer be seen histologically in the defect at 3 weeks, 
all of which suggests that the sheep cells were no longer 
present after 3 weeks, having been turned over during 
the rapid remodelling that occurs. The conclusion that 
events occurring early after implantation are critical to 
the success of healing agrees with recent data concerning 
the importance of mechanical and biological influences 
occurring in this period (Glatt et al., 2012; Schmidt-Bleek 
et al., 2014). These data are interesting in light of the 
observations of Sonnet et al. (2013) who, in a similar rat 
segmental defect model, obtained rapid healing with very 
low doses of BMP-2 delivered by encapsulated, genetically 
modified, allogeneic cells.
 Athymic rats are frequently used in studies of 
regenerative orthopaedics, and we were surprised to find 
a xenograft response to sheep cells. The ex vivo method 
used in this study eliminates immune responses to the 
adenovirus that was used (Evans et al., 2009). The presence 
of anti-sheep immune responses agrees with data from the 
Fig. 8. Effects of transient immunosuppression on bone healing in response to rhBMP-2. Radiology: Serial X-ray 
images (A1, A2) and µCT images at 8 weeks (B1, B2) of defects during healing in the absence (A1, B1) or presence 
(A2, B2) of immunosuppression. Arrows in panel A1, 8 weeks, indicate the original defect boundaries. Scale 
bars = 1 mm. Physical properties: Bone mineral content (C), Bone area (D), Total callus area (E), and Bone area/
Total area or Callus size (F, BA/TA, %).
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transplant literature indicative of xenograft responses in 
athymic rats (Xia et al., 2000), which are outbred. Using 
immunosuppressed wild-type rats as an alternative brings 
advantages of cost, availability and uniformity of the 
animals.
 Application of FK506 and SEW2871 raises the question 
of whether these immunosuppressive drugs enhance bone 
healing, as suggested by some studies (Voggenreiter et al., 
2000; Tang et al., 2002), thereby providing misleading 
results. However, bone did form in a sub-set of athymic rats, 
suggesting that the xenografted muscle did not require such 
drugs to form bone in these particular animals. Moreover, 
the immunosuppressive drugs had no major effects on 
healing of defects in Fischer 344 rats in response to 
rhBMP-2. This agrees with earlier observations that FK506 
has no effect on fracture healing in rats (Voggenreiter 
et al., 2005). The observation that genetically modified 
fat failed to provoke a robust osteogenic response in the 
immunosuppressed rats, despite expressing comparable 
amounts of BMP-2 to muscle, further suggests that the 
absence of an immune response is not responsible for the 
high effectiveness of muscle.
 Although fat is a more convenient source of donor 
tissue than muscle, its osteogenic properties in vivo were 
less reliable. The constituents of muscle that contribute to 
its higher osteogenic potential are unknown, but include 
osteoprogenitor cells, secreted osteogenic factors and 
components of the extracellular matrix. In preliminary 
experiments, we failed to trigger an osteogenic response in 
vivo by implanting decellularised muscle (data not shown). 
However, muscle is known to be a rich source of progenitor 
cells, including satellite cells, mesenchymal stem cells and 
muscle-derived stem cells (Judson et al., 2013), as well 
as endothelial cells from its blood vessels (Lounev et al., 
2009). The use of Ad.GFP to label transduced cells within 
muscle may help identify contributing cell types. Muscle 
also secretes multiple myokines (Pedersen, 2013), many of 
which could contribute to osteogenesis in conjunction with 
transgenic BMP-2. More research is required to elucidate 
these matters.
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Discussion with Reviewers
Reviewer I: At least two major story lines appear to be 
present in this paper (starting in the introduction): the 
role of immunosuppression on regeneration, the role of 
genetically modified muscle and fat tissue on bone defect 
healing, the comparison of bone and fat as origin of BMP 
transfected stimulation. Which story is the main story and 
how would you rank the others accordingly?
Authors: The flow of the discussion reflects the rank order 
of the “stories”. Thus, after an opening paragraph, there 
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is a paragraph with the lead story that: “The present data 
demonstrate that sheep skeletal muscle, transduced with 
Ad.BMP-2, can heal critical sized defects in vivo very 
effectively.” The following paragraph deals with what 
we consider to be the second most important finding, 
namely that the bone healing began rapidly and occurred 
under conditions of low and fairly transient BMP-2 
expression. The final paragraph starts “Application of 
FK506 and SEW2871 raises the question of whether 
immunosuppressive drugs enhance bone healing, …”, 
which we consider to be the next most interesting issue 
raised by our studies. At the end of this paragraph, we 
note that muscle is more effective than fat and discuss the 
components of muscle that could contribute to its high 
osteogenicity.
Reviewer II: What muscle-specific factors are likely to be 
responsible for enhanced fracture healing in combination 
with the expressed BMP-2? In addition to the presence 
of stem cells, and other trophic factors, does the muscle 
ECM also play a role, e.g. by facilitating attachment and 
recruitment of endogenous osteoblasts/osteoclasts. 
Authors: We conducted a preliminary experiment where 
decellularised muscle was implanted, but this failed to 
initiate osteogenesis. Thus, myokines or progenitor cells 
derived from muscle are more likely than extracellular 
matrix to play key roles in osteogenesis. The secretome of 
muscle is quite complex, and a number of different types 
of progenitor cells exist in muscle, so this will take some 
sorting out.
Reviewer II: How much is healing likely to be influenced 
by the anatomical site of skeletal tissue harvest? 
Authors: This is an interesting question. Because 
progenitor cells may be associated with blood vessels 
within muscle it is possible that, other things being equal, 
the more highly vascularised muscles are more osteogenic. 
Moreover, the vascularity of muscle increases with 
exercise. So there is every possibility that healing will be 
influenced by the anatomical site of muscle harvest, as well 
as the physiological status of the donor tissue.
Reviewer II: The repair response at 8 weeks was slightly 
inferior to intact bone with regard to cortical thickness and 
maximum torque. Does this represent the maximum repair 
response, or would further improved healing be anticipated 
at longer time points? If the response has reached a plateau, 
what modifications to the experimental approach could be 
adopted to improve healing even further?
Authors: Because the fixator remains in place during the 
whole experiment, it will continue to bear load and thus 
create stress shielding as healing progresses. It would be 
interesting to remove the fixator once osseous bridging 
has occurred to allow load bearing. This should enhance 
maturation and remodelling, thereby enhancing the quality 
of the healed bone.
Editor’s Note: Scientific Editor in charge of the paper: 
Martin Stoddart.
